Update on Sjogren's disease trials With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease. https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK